Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US-9339497-B2 · May 17, 2016 · US
Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
US9885087B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9885087-B2 |
| Application number | US-201514847304-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 8, 2015 |
| Priority date | Jul 5, 2011 |
| Publication date | Feb 6, 2018 |
| Grant date | Feb 6, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1. A monoclonal antibody which binds EGFR extracellular domain and comprises heavy chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 13, 14, and 15, respectively, and light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 16, 17 and 18, respectively. 2. A monoclonal antibody which binds EGFR extracellular domain and comprises a heavy chain variable region as set forth in SEQ ID NO: 23 and a light chain variable region as set forth in SEQ ID NO: 24. 3. The monoclonal antibody of claim 1 , wherein the antibody binds EGFR extracellular domain with a K D of better than 1 nM. 4. The monoclonal antibody of claim 1 , wherein the antibody is a human or humanized antibody. 5. The monoclonal antibody of claim 1 , wherein the antibody is an IgG1. 6. The monoclonal antibody of claim 2 , wherein the antibody is a human or humanized antibody. 7. The monoclonal antibody of claim 2 , wherein the antibody is an IgG1. 8. The monoclonal antibody of claim 3 , wherein the antibody is a human or humanized antibody. 9. The monoclonal antibody of claim 3 , wherein the antibody is an IgG1. 10. A composition comprising the monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier. 11. The composition according to claim 10 , which is a sterile composition. 12. The composition according to claim 11 , which is formulated for intravenous injection. 13. A composition comprising the monoclonal antibody of claim 2 and a pharmaceutically acceptable carrier. 14. The composition according to claim 13 , which is a sterile composition. 15. The composition according to claim 14 , which is formulated for intravenous injection. 16. A composition comprising the monoclonal antibody of claim 3 and a pharmaceutically acceptable carrier. 17. The composition according to claim 16 , which is a sterile composition. 18. The composition according to claim 17 , which is formulated for intravenous injection. 19. A composition comprising the monoclonal antibody of claim 5 and a pharmaceutically acceptable carrier. 20. A composition comprising the monoclonal antibody of claim 7 and a pharmaceutically acceptable carrier. 21. A composition comprising the monoclonal antibody of claim 9 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
of the prostate · CPC title
Drugs for disorders of the respiratory system · CPC title
involving intracellular compounds · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9885087B2 cover?
- Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
- Who is the assignee on this patent?
- Merrimack Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5758. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).